Slide 1: Investor Presentation November 2020
INVESTOR PRESENTATION November 2020
Slide 2: Safe harbour statement
Safe harbour statement The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested
Slide 3: Investment summary
Investment summary • Deoxymabs are the first antibody platform able to naturally enter cells and target DNA damage repair (DDR) • Recent transactions in cancer drugs targeting DDR, and sales of PARP inhibitors (2019/20 sales >US$1.5 bn) highlight the commercial attractiveness of this space • Patrys
Slide 4: Company snapshot
Company snapshot Shares 1.44B Patrys (ASX: PAB) – 12-month price an/d volume $0.03 90,000 Market cap A$30.2M 80,000 Cash 1 A$7.0M 70,000 Last qtr burn 1 (A$0.8M) $0.02 60,000 50,000 40,000 Headquarters Melbourne $0.01 30,000 Board John Read(Chair) 20,000 James Campbell (CEO & MD) 10,000 Pamela Klein
Slide 5: Board of Directors
Board of Directors John Read Chairman Dr Pamela M. Klein • Experienced Chairman and Director in public, • Former VP, Development at Genentech, led development private and government organisations of a large portfolio of drugs • Extensive career in venture capital, private • Chief Medical Officer of
Slide 6: Technology Overview
— Jiis ieee — le Technology Overview wad 7 ; a
Slide 7: First anticancer antibody therapeutic targeting DDR
First anticancer antibody therapeutic targeting DDR • Patients with systemic lupus erythematosis (SLE) generate antibodies against antigens from their own tissues and cells • An antibody which binds to DNA, 3E10, was isolated from a mouse model of SLE • 3E10 has a unique combination of properties th
Slide 8: Patrys' deoxymab platform
Patrys’ deoxymab platform • Patrys’ deoxymab platform is based on humanised versions of the mouse Mouse Humanised 3E10 antibodies • Global rights to 3E10 antibodies for the treatment of cancer were acquired in 2016 • Patrys has created humanised versions of the 3E10 antibodies for 3E10 - IgG PAT-DX3
Slide 9: Targeting DNA damage is effective for treating cancer
Targeting DNA damage is effective for treating cancer • Low-level damage occurs to DNA normally, but is usually fixed by DNA Normal tissues damage repair (DDR) systems DNA damage DNA damage repair (DDR) • Many current cancer treatments exploit the vulnerability cancer cells have from damage to their
Slide 10: Deoxymab platform offers multiple therapeutic approaches
Deoxymab platform offers multiple therapeutic approaches Single Agent Combination Therapies Targeted Therapies + • Many cancers have pre-existing defects • DNA damage can be increased by • Deoxymabs can direct delivery of toxic in their DNA damage repair (DDR) combining deoxymabs with existing DNA-
Slide 11: Deoxymab programs
— Jiis Ti ee — Deoxymab programs a8 & SO. hl A ae
Slide 12: Single agent – synthetic lethality is a proven approach
Single agent – synthetic lethality is a proven approach • Many cancer cells have defects in their DNA damage repair (DDR) systems • Redundancy means that these cancer cells usually can divide and survive, despite these defects • Further blocking the DDR systems with drugs can result in a build-up of
Slide 13: Single agent – deoxymabs offer new options
Single agent – deoxymabs offer new options • Patrys’ deoxymab platform provides an antibody option for generating Synthetic Lethality With Deoxymabs synthetic lethality to treat cancer • The potential benefits of using deoxymab antibodies for synthetic lethality include: • Cancer targeting: attracte
Slide 14: Single agent – deoxymabs for treatment of glioblastoma
Single agent – deoxymabs for treatment of glioblastoma • Glioblastoma (GBM) is the most common form of primary brain cancer, Glioblastoma cells with approximately 23,000 new cases diagnosed in the US each year control • GBM is highly aggressive with few effective treatment options (5-year Deoxymab s
Slide 15: Single agent – deoxymabs for breast cancer metastases
Single agent – deoxymabs for breast cancer metastases • Approximately 230,000 women are diagnosed with breast cancer in the US each year TNBC 1 Brain Metastases Model 100 • 10%-15% have Triple Negative Breast Cancer (TNBC), an aggressive form with deficiencies in the BRCA1 gene (DNA damage repair) 8
Slide 16: Single agent – many solid tumors have DDR mutations
Single agent – many solid tumors have DDR mutations Cancer incidence rates DDR mutation Opportunity (US cases p.a.)1 rates2 size 271k 16% 43k Breast Pancreatic 57k 15% 9k Ovarian 23k 20% 5k Endometerial 62k 34% 21k Colon 101k 15% 15k American Cancer Society - Cancer Facts & Figures 2019 Heeke et al.
Slide 17: Combination therapies – doubling down on DNA damage
Combination therapies – doubling down on DNA damage • Deoxymabs can be combined with radiation or chemotherapy drugs to increase the levels of DNA damage: Combination therapies • Radiation/chemo: damage DNA in cancer cells • Deoxymabs: reduce ability of cancer cells to repair DNA damage Chemo & PARP
Slide 18: Combination therapies – improving glioblastoma treatments
Combination therapies – improving glioblastoma treatments • Radiation is a mainstay treatment for glioblastoma (GBM) patients Radiation + Deoxymabs improve survival and is used: • as a monotherapy (less frequently) • post-surgical removal of tumour tissue 71% • in combination with the drug temozolom
Slide 19: Targeted therapies – Deoxymabs provide new opportunities
Targeted therapies – Deoxymabs provide new opportunities Cancer Targeting Nucleus Targeting x800 payload deoxymab alone + payload • Deoxymabs are attracted to the DNA released from tumors • Deoxymabs are able to enter the cell and penetrate into the nucleus • This “cancer seeking” activity can be us
Slide 20: Commercial landscape
Commercial landscape - 20 -
Slide 21: Recent deals for antibody and synthetic lethality assets
Recent deals for antibody and synthetic lethality assets US$6,000m Recent pre-clinical transactions (licensing, asset and corporate)1 US$4,000m US$4,000m US$3,065m US$2,070m US$1,700m US$1,076m US$1,200m US$600m US$269m Deal date 4Q18 1Q19 1Q19 2Q19 3Q19 1Q20 2Q20 2Q20 2Q20 3Q20 Co- Strategic Deal t
Slide 22: DDR assets attracting commercial interest
DDR assets attracting commercial interest - 22 -
Slide 23: Timeline
Timeline CY20 CY21 CY22 4Q 1Q 2Q 3Q 4Q 1Q 2Q Additional animal models PK and non - GLP Tox IND-enabling File GMP production and activities for MCB , USD and DSD and scale-up run formulation Aust-HREA (IND) PAT-DX1 Complete cell line GLP toxicology development Phase 1 Additional animal models (grants
Slide 24: Anticipated newsflow / Milestones
Anticipated newsflow / Milestones PAT-DX1 stable cell line development completed Q4 2020 PAT-DX1 & PAT-DX3 comparative animal studies initiated Q4 2020 PAT-DX1 non-GLP toxicology and pharmacokinetic studies completed Q1 2021 PAT-DX1 master call bank completed Q2 2021 PAT-DX3 pre-clinical studies ini
Slide 25: Risk factors
Risk factors - 25 -
Slide 26: Key Risks
Key Risks Investment in the Company involves risks that may be higher than the risks associated with an investment in other companies. Securities in the Company carry no guarantee with respect to the payment of dividends, returns of capital or the market value of the securities. Before deciding to i
Slide 27: Specific Risks - i
Specific Risks - i Innovative The Company's product range includes candidates that are in pre-clinical development and need to be technological further tested before they can progress to human clinical trials. Pre-clinical and clinical development of the development Company's product candidates coul
Slide 28: Specific Risks - ii
Specific Risks - ii Reliance on key The responsibility of overseeing the day-to-day operations and the strategic management of the personnel Company depends substantially on its senior management and its key personnel. There can be no assurance given that there will be no detrimental impact on the C
Slide 29: Specific Risks - iii
Specific Risks - iii Currency risk Revenue and expenditure in overseas jurisdictions are subject to the risk of fluctuations in foreign exchange markets. The Company carries on part of its business outside of Australia and intends to continue to do so. Accordingly, revenues and payments will be made
Slide 30: General Risks - i
General Risks - i Market Conditions The stock market, and in particular, the market for biotech companies, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of such companies. These factors may materially affect the
Slide 31: General Risks - ii
General Risks - ii Liquidity There can be no guarantee that an active market in the Securities will develop or that the price of the Securities will increase. There may be relatively few buyers or a relatively high number of sellers of Securities on ASX at any given time. This may increase the volat
Slide 32: General Risks - iii
General Risks - iii Taxation Risks Changes in tax law, or changes in the way tax laws are interpreted ,may impact the tax liabilities of the Company, Shareholder returns, or the tax treatment of a Shareholder’s investment. In particular, both the level and basis of taxation may change. Tax law is fr
Slide 33: Contact
CONTACT CONTACT Dr. James Campbell CEO and Managing Director +61 3 9670 3273 info@patrys.com www.patrys.com Patrys Limited (ASX:PAB)